Loading…

Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration

Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to m...

Full description

Saved in:
Bibliographic Details
Published in:Journal of analytical toxicology 2004-04, Vol.28 (3), p.160-167
Main Authors: Gustafson, Richard A, Kim, Insook, Stout, Peter R, Klette, Kevin L, George, M P, Moolchan, Eric T, Levine, Barry, Huestis, Marilyn A
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 167
container_issue 3
container_start_page 160
container_title Journal of analytical toxicology
container_volume 28
creator Gustafson, Richard A
Kim, Insook
Stout, Peter R
Klette, Kevin L
George, M P
Moolchan, Eric T
Levine, Barry
Huestis, Marilyn A
description Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P /= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71865980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71865980</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23</originalsourceid><addsrcrecordid>eNp9kMtOAyEYhVlobK2-gmHljgQKzMDSNN6SJm7qevJzaYoyMAJN7CP41k6ibl2dxTnfWXxnaEmZ6IjoO7pAl7W-Uco61fELtGCS0Z4JuURfryUkKCc8HaCMYPN7SL4FW3HeY8ZIyoVoYqGY_HkizscGmjTfChxOrmQLKYEJKUcM--YLtjm1kmP0DucCEf9LuDGkUOemhZyu0PkeYvXXv7lCu4f73eaJbF8enzd3WzJJIYny0mjecQCzFpRpDs5JKah0yjApnDdcrznnTrqul0ppq83Mqd6BceDXfIVuf26nkj-OvrZhDNX6GCH5fKxDz1QntaLz8OZ3eDSjd8NUwjiLGv7c8W-7S22N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71865980</pqid></control><display><type>article</type><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</creator><creatorcontrib>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</creatorcontrib><description>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P &lt;/= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration &gt;/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</description><identifier>ISSN: 0146-4760</identifier><identifier>PMID: 15107145</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Analgesics, Non-Narcotic - administration &amp; dosage ; Analgesics, Non-Narcotic - pharmacokinetics ; Cannabis ; Dosage Forms ; Dronabinol - administration &amp; dosage ; Dronabinol - analogs &amp; derivatives ; Dronabinol - pharmacokinetics ; Dronabinol - urine ; Gas Chromatography-Mass Spectrometry ; Half-Life ; Humans</subject><ispartof>Journal of analytical toxicology, 2004-04, Vol.28 (3), p.160-167</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15107145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gustafson, Richard A</creatorcontrib><creatorcontrib>Kim, Insook</creatorcontrib><creatorcontrib>Stout, Peter R</creatorcontrib><creatorcontrib>Klette, Kevin L</creatorcontrib><creatorcontrib>George, M P</creatorcontrib><creatorcontrib>Moolchan, Eric T</creatorcontrib><creatorcontrib>Levine, Barry</creatorcontrib><creatorcontrib>Huestis, Marilyn A</creatorcontrib><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><title>Journal of analytical toxicology</title><addtitle>J Anal Toxicol</addtitle><description>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P &lt;/= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration &gt;/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</description><subject>Administration, Oral</subject><subject>Analgesics, Non-Narcotic - administration &amp; dosage</subject><subject>Analgesics, Non-Narcotic - pharmacokinetics</subject><subject>Cannabis</subject><subject>Dosage Forms</subject><subject>Dronabinol - administration &amp; dosage</subject><subject>Dronabinol - analogs &amp; derivatives</subject><subject>Dronabinol - pharmacokinetics</subject><subject>Dronabinol - urine</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Half-Life</subject><subject>Humans</subject><issn>0146-4760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOAyEYhVlobK2-gmHljgQKzMDSNN6SJm7qevJzaYoyMAJN7CP41k6ibl2dxTnfWXxnaEmZ6IjoO7pAl7W-Uco61fELtGCS0Z4JuURfryUkKCc8HaCMYPN7SL4FW3HeY8ZIyoVoYqGY_HkizscGmjTfChxOrmQLKYEJKUcM--YLtjm1kmP0DucCEf9LuDGkUOemhZyu0PkeYvXXv7lCu4f73eaJbF8enzd3WzJJIYny0mjecQCzFpRpDs5JKah0yjApnDdcrznnTrqul0ppq83Mqd6BceDXfIVuf26nkj-OvrZhDNX6GCH5fKxDz1QntaLz8OZ3eDSjd8NUwjiLGv7c8W-7S22N</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>Gustafson, Richard A</creator><creator>Kim, Insook</creator><creator>Stout, Peter R</creator><creator>Klette, Kevin L</creator><creator>George, M P</creator><creator>Moolchan, Eric T</creator><creator>Levine, Barry</creator><creator>Huestis, Marilyn A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200404</creationdate><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><author>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Analgesics, Non-Narcotic - administration &amp; dosage</topic><topic>Analgesics, Non-Narcotic - pharmacokinetics</topic><topic>Cannabis</topic><topic>Dosage Forms</topic><topic>Dronabinol - administration &amp; dosage</topic><topic>Dronabinol - analogs &amp; derivatives</topic><topic>Dronabinol - pharmacokinetics</topic><topic>Dronabinol - urine</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Half-Life</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gustafson, Richard A</creatorcontrib><creatorcontrib>Kim, Insook</creatorcontrib><creatorcontrib>Stout, Peter R</creatorcontrib><creatorcontrib>Klette, Kevin L</creatorcontrib><creatorcontrib>George, M P</creatorcontrib><creatorcontrib>Moolchan, Eric T</creatorcontrib><creatorcontrib>Levine, Barry</creatorcontrib><creatorcontrib>Huestis, Marilyn A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of analytical toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gustafson, Richard A</au><au>Kim, Insook</au><au>Stout, Peter R</au><au>Klette, Kevin L</au><au>George, M P</au><au>Moolchan, Eric T</au><au>Levine, Barry</au><au>Huestis, Marilyn A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</atitle><jtitle>Journal of analytical toxicology</jtitle><addtitle>J Anal Toxicol</addtitle><date>2004-04</date><risdate>2004</risdate><volume>28</volume><issue>3</issue><spage>160</spage><epage>167</epage><pages>160-167</pages><issn>0146-4760</issn><abstract>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P &lt;/= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration &gt;/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</abstract><cop>England</cop><pmid>15107145</pmid><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0146-4760
ispartof Journal of analytical toxicology, 2004-04, Vol.28 (3), p.160-167
issn 0146-4760
language eng
recordid cdi_proquest_miscellaneous_71865980
source Oxford Journals Online; Alma/SFX Local Collection
subjects Administration, Oral
Analgesics, Non-Narcotic - administration & dosage
Analgesics, Non-Narcotic - pharmacokinetics
Cannabis
Dosage Forms
Dronabinol - administration & dosage
Dronabinol - analogs & derivatives
Dronabinol - pharmacokinetics
Dronabinol - urine
Gas Chromatography-Mass Spectrometry
Half-Life
Humans
title Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A05%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20pharmacokinetics%20of%2011-nor-9-carboxy-delta9-tetrahydrocannabinol%20after%20controlled%20oral%20delta9-tetrahydrocannabinol%20administration&rft.jtitle=Journal%20of%20analytical%20toxicology&rft.au=Gustafson,%20Richard%20A&rft.date=2004-04&rft.volume=28&rft.issue=3&rft.spage=160&rft.epage=167&rft.pages=160-167&rft.issn=0146-4760&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71865980%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71865980&rft_id=info:pmid/15107145&rfr_iscdi=true